Page 142 - Read Online

Page 16 of 18 Zhang et al. Hepatoma Res 2019;5:27 I http://dx.doi.org/10.20517/2394-5079.2019.13

116 Kurtz JE, Dufour P. Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside. Expert Opin Biol Ther
2010;10:951-8.
117 Campbell IG, Freemont PS, Foulkes W, Trowsdale J. An ovarian tumor marker with homology to vaccinia virus contains an IgV-like
region and multiple transmembrane domains. Cancer Res 1992;52:5416-20
118 Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a
therapeutic target for human solid tumors. Proc Natl Acad Sci U S A 2012;109:6662-7.
119 Brown EJ, Frazier WA. Integrin-associated protein (CD47) and its ligands. Trends Cell Biol 2001;11:130-5.
120 Chi HC, Lee KW, Ng OL. Abstract 2453: CD47 is a novel therapeutic target for hepatocellular carcinoma. Tumor Biology 2011;71:2453.
121 Chao MP, Weissman IL, Majeti R. The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications. Curr
Opin Immunol 2012;24:225-32.
122 Lo J, Lau EY, Ching RH, Cheng BY, Ma MK, et al. Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance
and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice. Hepatology 2015;62:534-45.
123 Casey SC, Tong L, Li Y, Do R, Walz S, et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science
2016;352:227-31.
124 Rodríguez MM, Fiore E, Bayo J, Atorrasagasti C, García M, et al. 4Mu Decreases CD47 Expression on Hepatic Cancer Stem Cells and
Primes a Potent Antitumor T Cell Response Induced by Interleukin-12. Mol Ther 2018;26:2738-50.
125 Jiang P, Lagenaur CF, Narayanan V. Integrin-associated protein is a ligand for the P84 neural adhesion molecule. J Biol Chem
1999;274:559-62.
126 Xiao Z, Chung H, Banan B, Manning PT, Ott KC, et al. Antibody mediated therapy targeting CD47 inhibits tumor progression of
hepatocellular carcinoma. Cancer Lett 2015;360:302-9.
127 Zhao XW, van Beek EM, Schornagel K, Van der Maaden H, Van Houdt M, et al. CD47-signal regulatory protein-α (SIRPα) interactions
form a barrier for antibody-mediated tumor cell destruction. Proc Natl Acad Sci U S A 2011;108:18342-7.
128 Yu XY, Qiu WY, Long F, Yang XP, Zhang C, et al. A novel fully human anti-CD47 antibody as a potential therapy for human neoplasms
with good safety. Biochimie 2018;151:54-66.
129. Park SC, Nguyen NT, Eun JR, Zhang Y, Jung YJ, et al. Identification of Cancer Stem Cell Subpopulations of CD34(+) PLC/PRF/5 That
Result in Three Types of Human Liver Carcinomas. Stem Cells Dev 2015;24:1008-1021.
130 Crosby HA, Kelly DA, Strain AJ. Human hepatic stem-like cells isolated using c-kit or CD34 can differentiate into biliary epithelium.
Gastroenterology 2001;120:534-44.
131. Zeng C, Zhang Y, Park SC, Eun JR, Nguyen NT, et al. CD34(+) Liver Cancer Stem Cells Were Formed by Fusion of Hepatobiliary Stem/
Progenitor Cells with Hematopoietic Precursor-Derived Myeloid Intermediates. 2015;24:2467-78.
132 Fujio K, Hu Z, Evarts RP, Marsden ER, Niu CH, et al. Coexpression of stem cell factor and c-kit in embryonic and adult liver. Exp Cell
Res 1996;224:243-50.
133 Rojas A, Zhang P, Wang Y, Foo WC, Muñoz NM, et al. A positive TGF-β/c-KIT feedback loop drives tumor progression in advanced
primary liver cancer. Neoplasia 2016;18:371-86.
134 Al-Shafie TA, Ismail A, Ashmawy AM, Elsayed AM, El-Houseini M. Inhibition of c-kit in late cirrhosis may restore TGF-β inhibitory
effect on somatic liver stem cells and prevent development of hepatocellular carcinoma. Life Sciences 2014;11.
135 Yan W, Zhu Z, Pan F, Huang A, Dai GH. Overexpression of c-kit (CD117), relevant with microvessel density, is an independent survival
prognostic factor for patients with HBV-related hepatocellular carcinoma. Onco Targets Ther 2018;11:1285-92.
136 Ashmun RA, Look AT. Metalloprotease activity of CD13/aminopeptidase N on the surface of human myeloid cells. Blood 1990;75:462-9.
137 Hashida H, Takabayashi A, Kanai M, Adachi M, Kondo K, et al. Aminopeptidase N is involved in cell motility and angiogenesis: its
clinical significance in human colon cancer. Gastroenterology 2002;122:376-86.
138 Liu LL, Fu D, Ma Y, Shen XZ. Development. The power and the promise of liver cancer stem cell markers. Stem Cells Dev 2011;20:2023-
30.
139 Petrovic N, Schacke W, Gahagan JR, O'Conor CA, Winnicka B, et al. CD13/APN regulates endothelial invasion and filopodia formation.
Blood 2007;110:142-50.
140. Nagano H, Ishii H, Marubashi S, Haraguchi N, Eguchi H, et al. Novel therapeutic target for cancer stem cells in hepatocellular carcinoma.
J Hepatobiliary Pancreat Sci 2012;19:600-605.
141. Kim HM, Haraguchi N, Ishii H, Ohkuma M, Okano M, et al. Increased CD13 expression reduces reactive oxygen species, promoting
survival of liver cancer stem cells via an epithelial–mesenchymal transition-like phenomenon. Ann Surg Oncol 2012;19:539-48.
142 Yamashita M, Wada H, Eguchi H, Ogawa H, Yamada D, et al. A CD13 inhibitor, ubenimex, synergistically enhances the effects of
anticancer drugs in hepatocellular carcinoma. Int J Oncol 2016;49:89-98.
143 Ji J, Wang XW. Clinical implications of cancer stem cell biology in hepatocellular carcinoma. Semin Oncol 2012;39:461-72.
144 Athanassiadou P, Grapsa D, Gonidi M, Athanassiadou AM, Tsipis A, et al. CD24 expression has a prognostic impact in breast carcinoma.
Pathol Res Pract 2009;205:524-33.
145 Huang LR, Hsu HC. Cloning and expression of CD24 gene in human hepatocellular carcinoma: a potential early tumor marker gene
correlates with p53 mutation and tumor differentiation. Cancer Res 1995;55:4717-21.
146 Liu AY, Cai Y, Mao Y, Lin Y, Zheng H, et al. Twist2 promotes self-renewal of liver cancer stem-like cells by regulating CD24.
Carcinogenesis 2014;35:537-45.
147 García K, Nabhani T, García J. The calcium channel α2/δ1 subunit is involved in extracellular signalling. J Physiol 2010;586:727-38.
148 Huang C, Li Y, Zhao W, Zhang A, Lu C, et al. α2δ1 may be a potential marker for tumor stem cell in laryngeal squamous cell carcinoma.